Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Oxford Lane Capital Implements 1-for-5 Reverse Stock Split and Announces New Distribution Schedule

Felix Baarz by Felix Baarz
September 13, 2025
in Analysis, Dividends, ETF
0
Oxford Lane Capital Stock
0
SHARES
152
VIEWS
Share on FacebookShare on Twitter

Oxford Lane Capital Corp. has completed a significant corporate action, implementing a 1-for-5 reverse stock split of its common stock. The shares of the closed-end fund began trading on a split-adjusted basis this Monday, prompting investor questions about the practical implications for their holdings and the company’s dividend distributions.

Revised Monthly Distribution Policy

In conjunction with the reverse split, the fund’s management has announced a recalibrated schedule for its monthly cash distributions. The updated payment details are as follows:

  • A distribution of $0.45 per share is scheduled for September 2025, with a record date of September 16.
  • For October 2025, a payment of $0.40 per share will be made to shareholders of record on October 17.
  • The November 2025 distribution is also set at $0.40 per share, with a record date of November 14.
  • A December 2025 payment of $0.40 per share will be distributed to investors on record as of December 17.

While the nominal distribution amounts appear larger, this is a direct result of the reduced number of shares outstanding following the reverse split. The fundamental economic value delivered to shareholders remains consistent with the company’s previous distribution policy.

Preliminary Net Asset Value Estimate Provided

The company’s management released a preliminary estimate of its net asset value (NAV) per share as of September 8, 2025. This estimate, which is already adjusted for the reverse split, places the NAV in a range between $20.02 and $20.22 per share.

A notable caution accompanies this estimate: the figure has not undergone the company’s standard quarterly financial closing procedures and is subject to change due to market movements. Consequently, the final NAV per share as of September 30, 2025, could differ materially from this preliminary range.

Should investors sell immediately? Or is it worth buying Oxford Lane Capital?

Share Repurchase Program Update

Oxford Lane continues to actively execute its share repurchase program. Between July 24, 2025, and August 13, 2025, the company bought back 4.9 million shares at a total cost of $17.4 million, reflecting an average price of $3.53 per share.

This repurchase activity is part of a broader $150 million authorization approved by the board of directors. The program is set to run through March 2026, and approximately $132.7 million remains available for future share buybacks.

Core CLO Investment Strategy Unchanged

The reverse split does not signal a shift in Oxford Lane Capital’s fundamental investment approach. The fund continues to specialize in investing in both debt and equity tranches of collateralized loan obligations (CLOs). Its portfolio also includes investments in warehouse facilities, which aggregate loans that may be used to form new CLOs.

This business model is designed to maximize risk-adjusted returns through these specialized credit investments. The recent reverse split and the accompanying adjustments to the distribution policy are strategic moves intended to optimize the company’s capital structure, aligning with the objectives of return-focused investors who have an interest in the CLO market.

Ad

Oxford Lane Capital Stock: Buy or Sell?! New Oxford Lane Capital Analysis from February 7 delivers the answer:

The latest Oxford Lane Capital figures speak for themselves: Urgent action needed for Oxford Lane Capital investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Oxford Lane Capital: Buy or sell? Read more here...

Tags: Oxford Lane Capital
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

February 7, 2026
Guaranty Bancshares Stock
Analysis

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
ServiceNow Stock
AI & Quantum Computing

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Next Post
Uranium Energy Stock

Uranium Energy Expands into Billion-Dollar Refining Market

Nvidia Stock

Is Nvidia's AI Dominance Facing Its First Real Test?

WideOpenWest Stock

Acquisition Bid for WideOpenWest Faces Mounting Scrutiny

Recommended

C3.ai Stock

Is C3.ai Stock Poised for a Rebound?

2 months ago
MMM stock news

Clarification on Hyperlink and Promotional Fees

2 years ago

XOMA Corporation Expands Portfolio with Acquisition of DSUVIA

2 years ago
Microsoft Stock

A Bold Bet: Peter Thiel’s Hedge Fund Doubles Down on Microsoft

1 month ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

ServiceNow Shares Face Market Skepticism Despite Record Performance

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

A New Chapter for First Busey as CrossFirst Merger Finalizes

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Trending

Avanos Medical Stock
Analysis

Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth

by SiterGedge
February 7, 2026
0

Avanos Medical is navigating a critical strategic transformation. The medical device firm is streamlining its operations to...

Guaranty Bancshares Stock

Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion

February 7, 2026
Yirendai Stock

Yirendai Charts a New Course with Tech-Driven Strategy

February 7, 2026
ServiceNow Stock

ServiceNow Shares Face Market Skepticism Despite Record Performance

February 7, 2026
Orthofix Medical Stock

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Avanos Medical’s Strategic Pivot: A Focus on High-Margin Growth
  • Guaranty Bancshares Sees Growth Accelerate Following Texas Expansion
  • Yirendai Charts a New Course with Tech-Driven Strategy

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com